Resveratrol up-regulates SIRT1 and inhibits cellular oxidative stress in the diabetic milieu: mechanistic insights.
Level 5 - mechanism / opinion, no new human data
In vitro bench research with observational human monocyte baseline comparison
PubMed 21813271 · doi:10.1016/j.jnutbio.2011.03.012
What was done
Monocytes from patients with Type 1 diabetes mellitus (T1DM) were compared with healthy controls for SIRT1 and p47phox expression. Human monocytic (THP-1) cells were cultured for 48 hours under normoglycemic (5.5 mmol/l glucose), hyperglycemic (25 mmol/l glucose), or mannitol osmolar control conditions, with or without resveratrol (3 and 6 μmol/l). SIRT1 small interfering RNA (siRNA) was used in high-glucose conditions to determine the pathway mechanism.
What was found
Monocytes from T1DM patients showed significantly decreased SIRT1 expression and increased p47phox expression compared with healthy controls. In THP-1 cells, high glucose decreased SIRT1 and FOXO3a while increasing superoxide production and p47phox; resveratrol reversed these changes. SIRT1 siRNA inhibited FOXO3a and eliminated resveratrol's protective effect under high glucose. The abstract reports no numerical values, effect sizes, or confidence intervals.
Why it matters
This paper identifies a specific molecular pathway (SIRT1-FOXO3a-p47phox) by which resveratrol mitigates cellular oxidative stress induced by high glucose in monocytes.
Limits
Participant sample size and demographics for the human comparison were not reported in the abstract. Interventions were strictly in vitro cell culture experiments using THP-1 cells, which do not account for human pharmacokinetics, bioavailability, or in vivo disease outcomes. No quantitative data were provided.
Cited by
- supports Sugar spikes suppress sirtuin enzyme activity.